Cellectis S.A. (CLLS) vs Quantum Cyber N.V. (QUCY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Quantum Cyber N.V. (QUCY) has outperformed Cellectis S.A. (CLLS) over the past year, losing 13.1% versus a loss of 70.9%. Cellectis S.A. is the larger company by market cap ($125.9 million vs $116.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | QUCY |
|---|---|---|
| Share price | $1.25 | $1.39 |
| Market cap | $125.90M | $116.85M |
| 1-day change | -6.72% | -2.80% |
| YTD return | -74.17% | +24.11% |
| 1-year return | -70.93% | -13.13% |
| 5-year return | -88.46% | — |
| EPS (TTM) | $-0.64 | $-2.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $4.93 |
| 52-week low | $1.22 | $0.30 |
| Distance from 52-week high | -77.19% | -71.81% |
| Analyst consensus | none | none |
| Avg. price target upside | +326.40% | +547.48% |
| Average volume | 80.14K | 691.24K |
| Shares outstanding | 72.72M | 84.07M |
| Employees | 224 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QUCY has outperformed CLLS by 57.8 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About Quantum Cyber N.V.
QUCY stock →Quantum Cyber N.V. operates as a technology company focused on cybersecurity and quantum computing solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
CLLS vs QUCY FAQ
Which is bigger, Cellectis S.A. or Quantum Cyber N.V.?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $125.90M compared with $116.85M for Quantum Cyber N.V. (QUCY).
Which stock has performed better over the past year, CLLS or QUCY?
QUCY returned -13.13% over the past 12 months, compared with -70.93% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and Quantum Cyber N.V. in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.